US FDA warning letter adds to Wockhardt's GMP woes
This article was originally published in Scrip
Executive Summary
The US FDA's latest warning letter against two of Wockhardt's Indian manufacturing sites has reiterated serious concerns about the integrity of data generated by the firm, which some analysts believe casts a deep shadow over resolution timelines given the unclear scope of current good manufacturing practice (cGMP) violations under scrutiny.